touchIMMUNOLOGY joins Professor Nicola Veronese (University of Padova, Italy) at WCO21 to discuss the efficacy, safety and quality of pharma-grade chondroitin sulfate in osteoarthritis treatment.
Questions
1. What is the rationale for the use of highly purified chondroitin sulfate (hpCS) in osteoarthritis treatment? (00:12-01:05)
2. Could you tell us a little about your recent literature review and its findings? (01:05-01:30)
3. What were your conclusions about the impact of efficacy, safety and health economics on treatment with hpCS? (01:30-02:35)
4. What are your thoughts on commonly available CS supplements and what can be done to ensure safe and effective products? (02:35-03:22)
5. Could you give us a brief overview of some of the other studies you are presenting at WCO? (03:22-04:05)
Disclosures: Nicola Veronese has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the WCO21 Annual Meeting.
